Search

Your search keyword '"Moroi S"' showing total 5 results
Start Over Author "Moroi S" Topic glaucoma
5 results on '"Moroi S"'

1. Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia.

Author

Kommaraju KR, Moroi S, and Demirci H

Subjects
Alemtuzumab, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Glaucoma drug therapy, Glucocorticoids administration & dosage, Humans, Immunosuppressive Agents administration & dosage, Injections, Spinal, Intraocular Pressure, Leukemia, Prolymphocytic, T-Cell drug therapy, Male, Middle Aged, Scleritis drug therapy, Uveitis, Anterior diagnosis, Uveitis, Anterior drug therapy, Visual Acuity physiology, Anterior Eye Segment pathology, Glaucoma diagnosis, Leukemia, Prolymphocytic, T-Cell diagnosis, Scleritis diagnosis
Abstract

Purpose: The aim of this study was to report a case of adult T-cell prolymphocytic leukemia (T-PLL), which presented with diffuse anterior scleritis and increased intraocular pressure., Methods: This is a case report., Results: A 57-year-old man presented with bilateral conjunctival hyperemia and chemosis associated with pain. He also complained of having fatigue, general weakness, and disequilibrium. His visual acuity was 20/20 bilaterally. His intraocular pressures were 34 mm Hg oculus dexter (OD) and 35 mm Hg oculus sinister (OS). His anterior segments were noted for moderate conjunctival injection, deep anterior chambers with +2 anterior chamber cells and flare, no abnormalities of iris structures, and mild nuclear sclerosis. His optic discs showed vertical cup-to-disc ratios of 0.4 oculus dexter and 0.7 oculus sinister. On B-scan ultrasonography, mild fluid in the sub-Tenon space and a thickening of the uvea were observed in both eyes. The patient was diagnosed with bilateral diffuse anterior scleritis and secondary glaucoma. Systemic evaluation revealed adult T-PLL with pulmonary, abdominal, and pelvic adenopathy; pleural effusion; and central nervous system (CNS) involvement. He was treated with systemic alemtuzumab and intrathecal alternating cytarabine/hydrocortisone and methotrexate/hydrocortisone. His lymphadenopathy decreased in size and the pleural effusion, scleritis, and secondary glaucoma resolved; however, his CNS disease was unresponsive. He was therefore given craniospinal irradiation with a total dose of 29.4 Gy. Despite radiotherapy, the CNS disease progressed, and the patient died 19 months after the presentation., Conclusions: Scleritis with secondary glaucoma, although usually associated with inflammatory conditions, can rarely be a manifestation of adult T-PLL.

Published
2014
Full Text
View/download PDF

3. Molecular biomarkers in glaucoma

Author

Bhattacharya, S. K., Lee, R. K., Grus, F. H., Bhattacharya, S, Grus, F, Lee, R, Beuerman, R, Burlingame, A, Coutinho, A, Crabb, J. W., Crowston, J, Dodel, R, Fingert, J, Hauser, M. A., John, S, Kaur, I, Martin, K, Miller, S, Pandey, A, Pasquale, L. R., Pericak-Vance, M, Petricoin, E, Pfeiffer, N, Ritch, R, Schmetterer, L, Tezel, G, Topouzis, F, Viswanathan, A, Weinreb, R, Wiggs, J. L., Zack, D, Zhou, Y, Asai, N, Bell, K, Bitoun, P, Boatright, J, Boehm, N, Bonakdar, M, Borras, T, Cao, J, Carper, D, Chin, H, Coca-Prados, M, Dong C., -J, Faunce, D, Fautsch, M, Flanagan, J, Gong, H, Gonzalez, H, Grishanin, R, Grosskreutz, C, Grunden, J, Hong, S, Hood, D, Ju W., -K, Junk, A, Kang, K. D., Karl, M, Kaufman, H, Kaufman, P, Khaw, P, Kim I., -B, Kirihara, T, Komaromy, A, Kramann, C, Liebmann, J, Lindsey, J, Lorenz, K, Mackey, D, Markabi, S, Mest, M, Miller, R, Moroi, S, O’Brien, J, O’Brien, C, Parikh, T, Park, S. C., Pe’Er, J, Petrash, J. M., Qu, J, Rittenhouse, K, Roberds, S, Sharif, N, Shepard, A, Sui, R, Toris, C, Traverso, C, Valorie, T, Weinmann, R, Wheeler, L, Whitlock, A, and Wirostko, B.

Subjects
Genetic Markers, Proteomics, medicine.medical_specialty, genetic structures, Glaucoma, Human health, Cellular and Molecular Neuroscience, Ophthalmology, Medicine, Humans, Biomarkers, Genomics, Metabolome, Sensory Systems, Medicine (all), Biomarker discovery, Blindness, business.industry, Articles, medicine.disease, Molecular biomarkers, eye diseases, Bench to bedside, Optometry, sense organs, business
Abstract

The seventh annual ARVO/Pfizer Ophthalmic Research Institute conference was held Friday and Saturday, April 29 and 30, 2011, at the Fort Lauderdale Hyatt Regency Pier 66, Fort Lauderdale, Florida. The conference, funded by The ARVO Foundation for Eye Research through a grant from Pfizer Ophthalmics, provided an opportunity to gather experts from within and outside ophthalmology to determine the state of knowledge pertaining to molecular biomarkers associated with glaucoma, as well as the methods to identify and validate them to predict (a) those who would be susceptible to development of glaucoma; (b) markers that will enable prediction of glaucoma progression; and (c) markers that will predict efficacy of treatment of glaucoma. Identification of such biomarkers will aid in prevention of glaucoma-related vision loss and blindness. The conference focused on an evaluation of glaucoma molecular biomarkers and progress needed for future validation of glaucoma biomarkers. A working group of 21 glaucoma researchers, 7 scientists focused on diseases other than glaucoma and with expertise in areas such as proteomic biomarkers or molecular mechanisms for neurodegeneration, and 60 observers from ARVO, Pfizer, and clinical and basic ophthalmic research convened to evaluate current understanding of the molecular biomarkers of glaucoma. The meeting format emphasized discussion and concentrated on questions within areas of glaucoma molecular biomarker research: Session I: How to define a biomarker in medicine? Current knowledge about biomarkers in human health and in glaucoma Session II: Genetic biomarkers in glaucoma Session III: Proteomic biomarkers in glaucoma Session IV: Pre-immune and immune events: Immunoproteomics and its possible applications in glaucoma Session V: From bench to bedside: How can a translational approach be successful? Each session began with a 10-minute overview by a glaucoma researcher followed by a 30-minute presentation by an outside expert, with parallels between their fields of expertise and the eye included. Invited outside experts covered several areas of research, including proteomic biomarker discovery in cancer (Emanuel Petricoin, PhD, George Mason University, Maryland; and Akhilesh Pandey, MD, PhD, Johns Hopkins University, Maryland) and astroglial cells in neurodegeneration (Stephen D. Miller, PhD, Northwestern University, Illinois).

Published
2013

4. Comment on “Clinical effectiveness of currently available low-vision devices in glaucoma patients with moderate-to-severe vision loss&rdquo

Author

Ehrlich JR and Moroi SE

Subjects
Glaucoma, Low Vision, Rehabilitation, Patient-Reported Outcomes, Mixed Methods, Ophthalmology, RE1-994
Abstract

Joshua R Ehrlich, Sayoko E MoroiDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USAWe read with great interest the article by Patodia et al entitled, “Clinical effectiveness of currently available low-vision devices in glaucoma patients with moderate-to-severe vision loss.”1 The authors presented a pilot randomized controlled trial (RCT) in which subjects with glaucoma and low vision were assigned to observation or to receive standard low vision device(s). Using the Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48), the researchers found an improvement in reading ability and overall visual ability among those allocated to treatment compared to the control arm.The authors correctly note that this is the first RCT to examine the effectiveness of low vision services for patients with glaucoma. In fact, there is also no rigorous evidence for the effectiveness of low vision interventions for patients with other causes of peripheral field loss (PFL) such as retinitis pigmentosa, hemianopia, or dense pan- retinal photogoagulation;2 this lack of evidence is concerning since around one-fifth of patients with low vision have been found to have significant PFL.3 Patodia et al1 point out that different patterns of functional impairment are likely to result from central and peripheral vision loss. Although this has been corroborated by prior research, there is still an inadequate qualitative understanding of how PFL affects patients’ day-to-day lives and how this is impacted by demographic and sociological features such as age, gender, culture, and place.View the original paper by Patodia et al.

Published
2017

5. Estrogen pathway polymorphisms in relation to primary open angle glaucoma: An analysis accounting for gender from the United States

Author

Pasquale, L. R., Loomis, S. J., Weinreb, R. N., Kang, J. H., Yaspan, B. L., Cooke Bailey, J., Gaasterland, D., Gaasterland, T., Lee, R. K., Scott, W. K., Lichter, P. R., Budenz, D. L., Liu, Y., Realini, T., Friedman, D. S., Catherine McCarty, Moroi, S. E., Olson, L., Schuman, J. S., Singh, K., Vollrath, D., Wollstein, G., Zack, D. J., Brilliant, M., Sit, A. J., Christen, W. G., Fingert, J., Kraft, P., Zhang, K., Allingham, R. R., Pericak-Vance, M. A., Richards, J. E., Hauser, M. A., Haines, J. L., and Wiggs, J. L.

Subjects
Male, Aging, genetic structures, Neurodegenerative, Ophthalmology & Optometry, Polymorphism, Single Nucleotide, Opthalmology and Optometry, Genetics, Humans, Genetic Predisposition to Disease, Polymorphism, Eye Disease and Disorders of Vision, Intraocular Pressure, Sex Characteristics, Neurosciences, Glaucoma, Estrogens, Single Nucleotide, Estrogen, eye diseases, United States, Open-Angle, Case-Control Studies, Female, sense organs, Glaucoma, Open-Angle, Metabolic Networks and Pathways, Research Article, Signal Transduction
Abstract

Purpose: Circulating estrogen levels are relevant in glaucoma phenotypic traits. We assessed the association between an estrogen metabolism single nucleotide polymorphism (SNP) panel in relation to primary open angle glaucoma (POAG), accounting for gender. Methods: We included 3,108 POAG cases and 3,430 controls of both genders from the Glaucoma Genes and Environment (GLAUGEN) study and the National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) consortium genotyped on the Illumina 660W-Quad platform. We assessed the relation between the SNP panels representative of estrogen metabolism and POAG using pathway-and gene-based approaches with the Pathway Analysis by Randomization Incorporating Structure (PARIS) software. PARIS executes a permutation algorithm to assess statistical significance relative to the pathways and genes of comparable genetic architecture. These analyses were performed using the metaanalyzed results from the GLAUGEN and NEIGHBOR data sets. We evaluated POAG overall as well as two subtypes of POAG defined as intraocular pressure (IOP) ≥22mmHg (high-pressure glaucoma [HPG]) or IOP 0.99). Among women, gene-based analyses revealed that the catechol-O-methyltransferase gene showed strong associations with HTG (permuted gene p≤0.001) and NPG (permuted gene p=0.01). Conclusions: The estrogen SNP pathway was associated with POAG among women. © 2013 Molecular Vision.

Catalog

Books, media, physical & digital resources
See catalog results